News

WHO Approves Groundbreaking Tuberculosis Diagnostic Test

Amazon Store

The World Health Organization (WHO) has granted prequalification to the Xpert MTB/RIF Ultra diagnostic test. This innovative test is the first to meet WHO’s stringent prequalification standards for TB diagnosis and antibiotic susceptibility testing.

TB is a major global health concern, causing over a million deaths annually and exerting immense socioeconomic burdens, particularly in low- and middle-income countries. The Xpert MTB/RIF Ultra test is designed to detect the genetic material of Mycobacterium tuberculosis, the bacterium responsible for TB, in sputum samples. It provides accurate results within hours and can identify mutations associated with rifampicin resistance, a key indicator of multidrug-resistant TB.

The WHO prequalification of this test is expected to ensure the quality of diagnostic tests used to improve access to early diagnosis and treatment. It also complements WHO’s endorsement approach, which considers emerging evidence, diagnostic accuracy, and patient outcomes alongside accessibility and equity.

According to Dr. Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products, “This first prequalification of a diagnostic test for tuberculosis marks a critical milestone in WHO’s efforts to support countries in scaling up and accelerating access to high-quality TB assays”.

The approval of the Xpert MTB/RIF Ultra test is a significant step forward in the fight against TB, enabling countries to address the dual burden of TB and drug-resistant TB.

WHO/Ruth Abla ADJORLOLO